Latest Board Refresh News

Page 1 of 14
Northern Star says KCGM commissioning is improving but remains beset by interruptions, with November availability at 72% and throughput up 15%. The update also puts the company’s rejected Gold Fields approach back in focus as new chief executive Suresh Vadnagra promises tighter operational and capital discipline.
Maxwell Dee
Maxwell Dee
18 Nov 2026
Rumble Resources has strengthened the development case for Western Queen with an underground-optimised resource, a projected A$133 million in free cash flow and a potential tungsten revenue stream. High-grade gold-copper drilling at Munarra Gully adds exploration momentum, but financing, approvals and feasibility work remain ahead.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Impact Minerals is recasting itself as a high-purity alumina developer, with Lake Hope advancing towards a definitive feasibility study and Alluminous reaching pilot-plant milestones. But the annual report also flags a material uncertainty over funding, while a board refresh and managing director departure add to the company’s transition.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Vantage Metals has intersected the key geological contact targeted by its maiden Botswana drilling campaign, with trace copper sulphides observed and assays pending. The exploration progress comes alongside A$723,000 in quarter-end cash, equivalent to just 0.3 quarters of estimated funding at the reported outflow rate.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Bubalus Resources will acquire the 494-square-kilometre Skyline copper-gold project in western Tasmania, close to the Mt Lyell mine, in a deal that could reshape its exploration portfolio. Completion depends on an approximately A$2.835 million capital raising, approvals and tenure conditions.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Argo Investments reported a stable $260.2 million profit for FY2026 with fully franked dividends rising to 38.5 cents per share. The LIC maintains a conservative investment approach, low costs, and strong governance as it marks 80 years.
Claire Turing
Claire Turing
3 Sept 2026
Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.
Ada Torres
Ada Torres
1 Sept 2026
Yandal Resources shakes up its leadership with the appointment of seasoned geologist Eduard Eshuys as Non-Executive Chair and the departure of CEO Chris Oorschot, signaling a pivotal moment as the company advances its gold exploration projects in Western Australia.
Maxwell Dee
Maxwell Dee
1 Sept 2026
Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.
Ada Torres
Ada Torres
31 Aug 2026
ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.
Sophie Babbage
Sophie Babbage
31 Aug 2026
BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.
Sophie Babbage
Sophie Babbage
31 Aug 2026
OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.
Ada Torres
Ada Torres
28 Aug 2026

Browse the archive

Full archive